Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 8;77(22):2822-2845.
doi: 10.1016/j.jacc.2021.01.060.

Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8

Marc S Sabatine  1 , Eugene Braunwald  2
Affiliations
Free article
Review

Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8

Marc S Sabatine et al. J Am Coll Cardiol. .
Free article

Abstract

In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born. Following completion of 3 clinical trials of thrombolytic therapy supported by the NHLBI, TIMI became an academic research organization headquartered at Brigham and Women's Hospital and subsequently branched out to study a wide range of patients, including those with stable coronary, cerebrovascular, and peripheral arterial disease; dyslipidemia; heart failure; atrial fibrillation; diabetes; and obesity. TIMI also began to study a wide range of interventions including thrombolytic, antithrombotic, lipid-modifying, anti-inflammatory, heart failure, glucose-lowering, and weight loss agents. TIMI, now in its 37th year, has completed >70 trials. This review describes the origins of the TIMI Study Group, summarizes several of its completed trials and the major lessons learned from them, and discusses ongoing trials and future directions.

Keywords: clinical trials; historical review; risk assessment; thrombolysis.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr. Sabatine has received research grant support through Brigham and Women’s Hospital from Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, The Medicines Company, MedImmune, Merck, Novartis, and Pfizer; and has provided consulting services to Althera, Amgen, Anthos Therapeutics, AstraZeneca, Bristol Myers Squibb, DalCor, Dr. Reddy’s Laboratories, Intarcia, and Merck. Dr. Braunweld has received research grant support through Brigham and Women’s Hospital from AstraZeneca, Daiichi-Sankyo, Merck, and Novartis; and has provided consulting services to Amgen, Boehringer Ingelheim/Lilly, Cardurion, MyoKardia, NovoNordisk, and Verve.

LinkOut - more resources